Posters

In vitro behavior of different ophthalmic viscosurgical devices on the corneal endothelium during cataract surgery

Poster Details

First Author: T.Yildirim GERMANY

Co Author(s):    H. Son   P. Merz   G. Auffarth              

Abstract Details

Purpose:

To quantify the amount of corneal endothelial surface coverage and corneal endothelial cell loss during cataract surgery with different dispersive and cohesive Ophthalmic Viscosurgical Devices (OVDs) from various manufacturers in a wet lab setup using porcine eyes.

Setting:

The David J Apple International Laboratory for Ocular Pathology, Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany

Methods:

Freshly enucleated porcine eyes were prepared for imaging of the corneal endothelium using fluorescent stained OVDs. After creating a clear corneal incision the anterior chamber was filled with stained OVD. After capsulorhexis the lens content was removed by phacoemulsification without bimanual irrigation/aspiration [I/A]. After surgery, the cornea was cut and turned to reveal its posterior surface. By applying blue light (420 to 500 nm) the area of fluorescing endothelium in relation to its total surface could be determined using planimetric image-analysis software (ImageJ). Endothelial cell count was obtained after cataract surgery and compared with cell count of a control cornea.

Results:

6 different OVDs from 2 groups were used: Dispersive HA- or HPMC-based OVDs (Healon EndoCoat [Johnson & Johnson Vision], Viscoat [Alcon], Methylvisc [Rayner]) and cohesive HA-based OVDs (Healon, Healon GV [Johnson & Johnson Vision]; ProVisc [Alcon]). The least endothelial coating was observed in the cohesive group while the dispersive group showed statistically significant higher adherence to the endothelium. Endothelial cell loss was higher in the cohesive group.

Conclusions:

The dispersive HA and HPMC based OVDs with a low molecular weight showed a greater adherence to the endothelial surface than the cohesive HA OVDs with a higher molecular weight leading to a potentially better protection of the endothelium.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives non-monetary benefits from a competing company., receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented., receives consulting fees, retainer, or contract payments from a competing company